Inozyme Pharma upgraded by Jefferies with a new price target
$INZY
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies upgraded Inozyme Pharma from Hold to Buy and set a new price target of $6.00 from $4.50 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2024 | $26.00 | Outperform | Raymond James |
| 9/12/2024 | $16.00 | Buy | Stifel |
| 8/13/2024 | $16.00 → $17.00 | Buy | Jefferies |
| 5/30/2024 | $14.00 | Overweight | Wells Fargo |
| 3/23/2023 | $4.50 → $6.00 | Hold → Buy | Jefferies |
| 5/26/2022 | $5.00 | Hold | Jefferies |
| 2/7/2022 | $33.00 | Buy | HC Wainwright & Co. |
| 11/29/2021 | $23.00 | Buy | Needham |
SC TO-T/A - Inozyme Pharma, Inc. (0001693011) (Subject)
SCHEDULE 13G - Inozyme Pharma, Inc. (0001693011) (Subject)
SC 14D9/A - Inozyme Pharma, Inc. (0001693011) (Subject)
4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
4 - Inozyme Pharma, Inc. (0001693011) (Issuer)